BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 12738788)

  • 1. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells.
    Fujita T; Kobayashi Y; Wada O; Tateishi Y; Kitada L; Yamamoto Y; Takashima H; Murayama A; Yano T; Baba T; Kato S; Kawabe Y; Yanagisawa J
    J Biol Chem; 2003 Jul; 278(29):26704-14. PubMed ID: 12738788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains.
    Métivier R; Penot G; Flouriot G; Pakdel F
    Mol Endocrinol; 2001 Nov; 15(11):1953-70. PubMed ID: 11682626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
    Keeton EK; Brown M
    Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes.
    Yamamoto Y; Wada O; Suzawa M; Yogiashi Y; Yano T; Kato S; Yanagisawa J
    J Biol Chem; 2001 Nov; 276(46):42684-91. PubMed ID: 11553641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
    Morrison AJ; Herrera RE; Heinsohn EC; Schiff R; Osborne CK
    Mol Endocrinol; 2003 Aug; 17(8):1543-54. PubMed ID: 12730327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
    Nichols M; Cheng P; Liu Y; Kanterewicz B; Hershberger PA; McCarty KS
    Breast Cancer Res Treat; 2010 Apr; 120(3):761-8. PubMed ID: 19526339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.
    Klinge CM; Jernigan SC; Mattingly KA; Risinger KE; Zhang J
    J Mol Endocrinol; 2004 Oct; 33(2):387-410. PubMed ID: 15525597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
    Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
    J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
    Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
    Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha.
    Gougelet A; Mueller SO; Korach KS; Renoir JM
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):110-22. PubMed ID: 17478088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
    Sakamoto T; Eguchi H; Omoto Y; Ayabe T; Mori H; Hayashi S
    Mol Cell Endocrinol; 2002 Jun; 192(1-2):93-104. PubMed ID: 12088871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogenic activity and metabolism of n-butyl benzyl phthalate in vitro: identification of the active molecule(s).
    Picard K; Lhuguenot JC; Lavier-Canivenc MC; Chagnon MC
    Toxicol Appl Pharmacol; 2001 Apr; 172(2):108-18. PubMed ID: 11298497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
    Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
    Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
    Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
    Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells.
    Rousseau C; Pettersson F; Couture MC; Paquin A; Galipeau J; Mader S; Miller WH
    J Steroid Biochem Mol Biol; 2003 Jul; 86(1):1-14. PubMed ID: 12943740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo.
    Liu XF; Bagchi MK
    J Biol Chem; 2004 Apr; 279(15):15050-8. PubMed ID: 14722073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
    Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.